Aimedbio signed a license agreement with Boehringer Ingelheim worth up to $991 million to develop and commercialize a preclinical antibody‑drug conjugate targeting solid tumors, including KRAS‑mutant cancers. The asset is expected to enter a phase I study next year. Aimedbio, an ADC specialist, will hand the program to Boehringer to advance clinical development and global commercialization under the terms disclosed Oct. 16, 2025.